In the BioHarmony Drug Report Database

"Preview" Icon

Viloxazine

Qelbree (viloxazine) is a small molecule pharmaceutical. Viloxazine was first approved as Qelbree on 2021-04-02. It is used to treat depression in the USA. Qelbree’s patent is valid until 2033-02-07 (FDA).

 

Trade Name

 

Qelbree
 

Common Name

 

viloxazine
 

ChEMBL ID

 

CHEMBL306700
 

Indication

 

depression
 

Drug Class

 

Antidepressant; Norepinephrine reuptake inhibitor

Image (chem structure or protein)

Viloxazine structure rendering